1. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32–42.
2. Shakeel F, Iqbal M, Ezzeldin E, et al. Bioavailability enhancement and pharmacokinetic profile of an anticancer drug ibrutinib by self-nanoemulsifying drug delivery system. J Pharm Pharmacol 2016; 68(6): 772–780.
3. Kamel S, Horton L, Ysebaert L, et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia 2015; 29: 783–787.
4. Farooqui M, Lozier JN, Valdez J, et al. Ibrutinib (PCI 32765) rapidly improves platelet counts in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients and has minimal effects on platelet aggregation. ASH Annual Meeting Abstracts 2012; 120: 1789.
5. Harrison P, Mackie I, Mumford A, et al. British Committee for Standards in Haematology. Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol 2011; 155: 30–44.
6. Ezumi Y, Shindoh K, Tsuji M, Takayama H. Physical and functional association of the Src family kinases Fyn and Lyn with the collagen receptor glycoprotein VI-Fc receptor γ-chain complex on human platelets. J Exp Med 1998; 188: 267–276.
7. Wonerow P, Pearce AC, Vaux DJ, Watson SP. A critical role for phospholipase Cγ2 in αIIbβ3-mediated platelet spreading. J Biol Chem 2003; 278: 37520–37529.
8. Lowry WE, Huang X-Y. G Protein βγ subunits act on the catalytic domain to stimulate Bruton’s agammaglobulinemia tyrosine kinase. J Biol Chem 2002; 277: 1488–1492.